Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

541
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
541
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

286
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
286
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

753
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
753
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

238
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
238
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

240
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
240
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

20
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
20

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Relative Bioavailability of Lutein and Zeaxanthin in the Presence of Omega-3 Supplements and Their Effect on Oxidative Stress Levels in Humans: A Pilot Study.

Nutrients·2026
Same author

Could contact lens dryness discomfort symptoms sometimes have a neuropathic basis?

Eye and vision (London, England)·2021
Same author

Aqueous deficiency is a contributor to evaporation-related dry eye disease.

Eye and vision (London, England)·2020
See all related articles

Related Experiment Video

Updated: Oct 18, 2025

A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies
08:04

A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies

Published on: January 24, 2020

12.6K

Transdermal anti-inflammatory therapy for aqueous deficiency.

Charles W McMonnies1

  • 1Faculty of Medicine and Health, School of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, Australia.

Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists)
|October 4, 2021
PubMed
Summary

Topical anti-inflammatory drugs poorly reach the lacrimal gland, limiting their effectiveness in treating dry eye disease. Alternative delivery methods are needed to improve drug access and aqueous flow for dry eye patients.

Keywords:
aqueous deficiencylacrimal gland inflammationtransdermal drug delivery

More Related Videos

Establishment of A Mouse Model of Aqueous Deficiency Dry Eye
05:21

Establishment of A Mouse Model of Aqueous Deficiency Dry Eye

Published on: November 1, 2024

812
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.5K

Related Experiment Videos

Last Updated: Oct 18, 2025

A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies
08:04

A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies

Published on: January 24, 2020

12.6K
Establishment of A Mouse Model of Aqueous Deficiency Dry Eye
05:21

Establishment of A Mouse Model of Aqueous Deficiency Dry Eye

Published on: November 1, 2024

812
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.5K

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Lacrimal gland inflammation significantly impairs aqueous production, contributing to dry eye disease.
  • Ocular surface inflammation in dry eye can result from reduced aqueous delivery from an inflamed lacrimal gland.
  • Inflamed lacrimal glands release high concentrations of inflammatory mediators.

Purpose of the Study:

  • To review evidence on the limited access of topical anti-inflammatory drugs to the lacrimal gland.
  • To examine challenges in treating dry eye disease with topical anti-inflammatory drugs, using cyclosporine as an example.
  • To compare topical drug delivery limitations with the potential of transdermal applications for treating aqueous deficiency.

Main Methods:

  • Review of existing scientific literature on drug delivery to the lacrimal gland.
  • Analysis of therapeutic challenges associated with topical anti-inflammatory drug administration in dry eye.
  • Comparison of topical ocular drug delivery with transdermal delivery strategies.

Main Results:

  • Topical anti-inflammatory drugs demonstrate limited access to the lacrimal gland.
  • Poor drug access to the lacrimal gland is a significant barrier to treating aqueous deficiency.
  • Drug efficacy is hindered by short on-eye residence times and suboptimal drop characteristics (temperature, pH, tonicity).

Conclusions:

  • Current topical anti-inflammatory treatments have limited capacity to increase aqueous flow by reducing lacrimal gland inflammation.
  • Transdermal drug delivery presents a potential alternative for achieving prolonged therapeutic effects at the lacrimal gland.
  • Addressing poor lacrimal gland drug penetration is crucial for advancing dry eye disease treatment.